These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

66 related items for PubMed ID: 7675451

  • 21. Tyrosine phosphorylation of Shc proteins and formation of Shc/Grb2 complex correlate to the transformation of NIH3T3 cells mediated by the point-mutation activated neu.
    Xie Y, Li K, Hung MC.
    Oncogene; 1995 Jun 15; 10(12):2409-13. PubMed ID: 7784091
    [Abstract] [Full Text] [Related]

  • 22. Interaction with the phosphotyrosine binding domain/phosphotyrosine interacting domain of SHC is required for the transforming activity of the FLT4/VEGFR3 receptor tyrosine kinase.
    Fournier E, Rosnet O, Marchetto S, Turck CW, Rottapel R, Pelicci PG, Birnbaum D, Borg JP.
    J Biol Chem; 1996 May 31; 271(22):12956-63. PubMed ID: 8662748
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Mutation of Tyr697, a GRB2-binding site, and Tyr721, a PI 3-kinase binding site, abrogates signal transduction by the murine CSF-1 receptor expressed in Rat-2 fibroblasts.
    van der Geer P, Hunter T.
    EMBO J; 1993 Dec 15; 12(13):5161-72. PubMed ID: 8262059
    [Abstract] [Full Text] [Related]

  • 25. Signal transduction in human hematopoietic cells by vascular endothelial growth factor related protein, a novel ligand for the FLT4 receptor.
    Wang JF, Ganju RK, Liu ZY, Avraham H, Avraham S, Groopman JE.
    Blood; 1997 Nov 01; 90(9):3507-15. PubMed ID: 9345034
    [Abstract] [Full Text] [Related]

  • 26. Requirement of both tyrosine residues 1330 and 1337 in the C-terminal tail of the RON receptor tyrosine kinase for epithelial cell scattering and migration.
    Xiao ZQ, Chen YQ, Wang MH.
    Biochem Biophys Res Commun; 2000 Jan 19; 267(2):669-75. PubMed ID: 10631120
    [Abstract] [Full Text] [Related]

  • 27. Overexpression confers an oncogenic potential upon the eph gene.
    Maru Y, Hirai H, Takaku F.
    Oncogene; 1990 Mar 19; 5(3):445-7. PubMed ID: 2314900
    [Abstract] [Full Text] [Related]

  • 28. Identification of a novel activated form of the keratinocyte growth factor receptor by expression cloning from parathyroid adenoma tissue.
    Sakaguchi K, Lorenzi MV, Matsushita H, Miki T.
    Oncogene; 1999 Sep 30; 18(40):5497-505. PubMed ID: 10523826
    [Abstract] [Full Text] [Related]

  • 29. MET(PRC) mutations in the Ron receptor result in upregulation of tyrosine kinase activity and acquisition of oncogenic potential.
    Williams TA, Longati P, Pugliese L, Gual P, Bardelli A, Michieli P.
    J Cell Physiol; 1999 Dec 30; 181(3):507-14. PubMed ID: 10528237
    [Abstract] [Full Text] [Related]

  • 30. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development.
    Kaipainen A, Korhonen J, Mustonen T, van Hinsbergh VW, Fang GH, Dumont D, Breitman M, Alitalo K.
    Proc Natl Acad Sci U S A; 1995 Apr 11; 92(8):3566-70. PubMed ID: 7724599
    [Abstract] [Full Text] [Related]

  • 31. Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase.
    Irrthum A, Karkkainen MJ, Devriendt K, Alitalo K, Vikkula M.
    Am J Hum Genet; 2000 Aug 11; 67(2):295-301. PubMed ID: 10856194
    [Abstract] [Full Text] [Related]

  • 32. Overexpression of the Sky receptor tyrosine kinase at the cell surface or in the cytoplasm results in ligand-independent activation.
    Taylor IC, Roy S, Varmus HE.
    Oncogene; 1995 Dec 21; 11(12):2619-26. PubMed ID: 8545119
    [Abstract] [Full Text] [Related]

  • 33. Vascular endothelial growth factor receptor-3.
    Taipale J, Makinen T, Arighi E, Kukk E, Karkkainen M, Alitalo K.
    Curr Top Microbiol Immunol; 1999 Dec 21; 237():85-96. PubMed ID: 9893347
    [No Abstract] [Full Text] [Related]

  • 34. Structure, expression, and activity of Tyro 3, a neural adhesion-related receptor tyrosine kinase.
    Lai C, Gore M, Lemke G.
    Oncogene; 1994 Sep 21; 9(9):2567-78. PubMed ID: 8058320
    [Abstract] [Full Text] [Related]

  • 35. Fibroblast growth factor receptor tyrosine kinases: molecular analysis and signal transduction.
    Jaye M, Schlessinger J, Dionne CA.
    Biochim Biophys Acta; 1992 Jun 10; 1135(2):185-99. PubMed ID: 1319744
    [No Abstract] [Full Text] [Related]

  • 36. Expression of the FLT4/VEGFR3 receptor tyrosine kinase encoding gene in hepatic tumors.
    Karamysheva A, Shushanov S, Adelaide J, Kakpakova E, Abdryashitov R, Stavrovskaya A, Birnbaum D.
    Int J Oncol; 1996 May 10; 8(5):921-4. PubMed ID: 21544446
    [Abstract] [Full Text] [Related]

  • 37. Cell signalling. Receptor orphans find a family.
    Pandey A, Lindberg RA, Dixit VM.
    Curr Biol; 1995 Sep 01; 5(9):986-9. PubMed ID: 8542290
    [Abstract] [Full Text] [Related]

  • 38. Vascular and lymphatic regulation of gastrointestinal function and disease risk.
    Cifarelli V, Peche VS, Abumrad NA.
    Biochim Biophys Acta Mol Cell Biol Lipids; 2022 Nov 01; 1867(11):159207. PubMed ID: 35882297
    [Abstract] [Full Text] [Related]

  • 39. The adaptor protein Grb2b is an essential modulator for lympho-venous sprout formation in the zebrafish trunk.
    Mauri C, van Impel A, Mackay EW, Schulte-Merker S.
    Angiogenesis; 2021 May 01; 24(2):345-362. PubMed ID: 33677657
    [Abstract] [Full Text] [Related]

  • 40. Two Birds, One Stone: Double Hits on Tumor Growth and Lymphangiogenesis by Targeting Vascular Endothelial Growth Factor Receptor 3.
    Hsu MC, Pan MR, Hung WC.
    Cells; 2019 Mar 21; 8(3):. PubMed ID: 30901976
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.